Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence of major cardiovascular events compared…
Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an antisense oligonucleotide lowering lipoprotein(a)—both failed…
Two randomized trials conducted in China found that endovascular therapy improved functional outcomes in patients with acute ischemic stroke caused…
A meta-analysis of 15 randomized controlled trials involving 4,824 patients with high blood pressure found that sacubitril/valsartan significantly improved multiple…
In patients with intermediate-high–risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus anticoagulation significantly reduced the 7-day risk of death,…
In patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), aficamten significantly improved exercise capacity and patient-reported health status compared with placebo…
In patients with atrial fibrillation at intermediate risk for stroke, direct oral anticoagulant (DOAC) therapy significantly reduced the 24-month risk…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD) who were taking statins for…
Intensive blood pressure (BP) control targeting <130/80 mm Hg reduced cardiovascular events and mortality consistently across all baseline diastolic blood…
In patients with ST-segment elevation myocardial infarction (STEMI), early subcutaneous administration of zalunfiban significantly improved coronary artery patency and reduced…
This website uses cookies.